CTXR
Citius Pharmaceuticals, Inc.
$0.56
-0.03 (-4.62%)
At close · Jul 8
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred a net loss of $37,503,635 for the six months ended March 31, 2026. The Company experienced negative cash flows from operations of $14,308,843 for the six months ended March 31, 2026. At March 31, 2026, the Company had $4,590,174 in cash and a negative working capital of approximately $23.3 million.”View the 10-Q filed May 15, 2026
Market Cap
$15.30M
Shares
27,452,570
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.56
Open$0.60
Day$0.55–0.60
52W$0.48–2.19
Avg vol 30d313K
Short int4.9M · 17.8% float · 14.7d
Short vol25%
Last earningsAug 12, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
−9%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
5%
near low
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−35%
trailing
YTD return
−28%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.79% of float · ▼ -1.3% MoM · 14.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
39 holders — near 1-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-26.6M
Balance sheet
$4.3M
net cash
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.79% of float · ▼ -1.3% MoM · 14.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
39 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $1 · 5%
52-wk high $2
vs 200-day avg -39%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| gross margins | 80% | fiscal second quarter 2026 | — |
| of target accounts had added or were actively progressing LYMPHIR through formulary review | 83% | fiscal second quarter 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTXR
this stock
Citius Pharmaceuticals, Inc.
|
$15.30M | -28.3% | — | — | 17.8% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTXR | -7.9% | -5.4% | -35.0% | -7.9% | -28.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -7.8% | -6.3% | -42.5% | -7.8% | -37.6% |